1. Introduction
===============

Cerebral hemorrhage (CH) is a very common cerebrovascular disorder in clinical practice.^\[[@R1]--[@R3]\]^ Patients who experience such disorder often have difficulty in walking, speaking, and understanding, and paralysis or numbness of the face, arm, or leg, which significantly affect their health-related quality of life.^\[[@R4]--[@R6]\]^ Furthermore, it also causes high morbidity and mortality in patients with CH.^\[[@R7]--[@R9]\]^ It has been estimated that the mortality rate in such patients can reach 40% to 50%, and 75% of those survivors cannot live independently 1 year post stroke.^\[[@R10]\]^

Many factors can cause CH, especially for pregnant women, such as gestational hypertension (GH).^\[[@R5],[@R11],[@R12]\]^ GH is a major predictor of pregnancy-associated CH.^\[[@R13],[@R14]\]^ Several managements are responsible for patients with CH secondary to the GH, including microsurgery, medication, acupuncture, moxibustion, and Tuina, especially for microsurgery.^\[[@R15]--[@R22]\]^ A variety of studies have reported that microsurgery is an effective management for patients with CH secondary to the GH.^\[[@R4],[@R22]--[@R24]\]^ However, convinced evidence-based level is still needed to support this therapy. Therefore, this study aims to summarize and critically assess the evidence from current clinical studies that have investigated the efficacy of microsurgery as a treatment for patients with CH secondary to the GH.

2. Methods
==========

2.1. Study selection criteria
-----------------------------

### 2.1.1. Types of studies

We will consider randomized controlled trials (RCTs) comparing microsurgery with other treatment. However, case studies, case-control studies, reviews, and non-RCTs will be excluded.

### 2.1.2. Types of interventions

The participants in the experimental group must receive microsurgery for CH secondary to GH.

The participants in the control group can receive any treatments, except microsurgery.

### 2.1.3. Types of participants

Pregnant participants of any age with clinically diagnosed as CH secondary to GH will be considered for inclusion.

### 2.1.4. Types of outcome measurements

The outcomes comprise of maternal mortality, severe maternal complications (such as number of participants with pre-eclampsia, pre-term labor, and pregnancy loss), maternal quality of life (as measured by Maternal Perceived Quality of Life, or relevant scales), limbs function, muscle strength, and muscle tone.

2.2. Search strategy
--------------------

The electronic databases of Cochrane Library, PUBMED, EMBASE, Web of Science, VIP, WANFANG, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure will be searched from inceptions to the present without language limitation. The detailed strategy for searching the Cochrane Library will be shown in Table [1](#T1){ref-type="table"}. Similar detailed search strategies will be modified and adapted to other electronic databases.
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In addition, clinical trials registry, conference proceedings, dissertations, and reference lists of included studies will be searched.

2.3. Data collection and analysis
---------------------------------

### 2.3.1. Study selection

Two authors will independently scan the titles and abstracts of all literature identified, and all irrelevant records and duplicated studies will be excluded. The remaining studies will be subsequently screened by reading full-text. In the event of divergences between two authors that they can not solve via discussion, and a third author will be consulted, who can help make the decision. The whole process of study selection will be presented in flowchart.

### 2.3.2. Data extraction

Data from the eligible studies will be extracted and collected by two authors independently according to the previous designed data extraction sheet. Any disagreements will be resolved by consensus with the help of a third author. We will collect information, such as title, first author, publication year, characteristics of study and patients, study methods, treatment details, outcome indicators, adverse events, and follow-up details. We will contact primary authors of trials for further information when necessary.

### 2.3.3. Missing data dealing with

We will try to require information by contacting corresponding author of the primary studies for the missing, unclear or insufficient data. If we cannot obtain these data, only available data will be analyzed based on the intent-to-treat principle.

### 2.3.4. Risk of bias assessment

The risk of bias will be assessed by two independent authors using Cochrane risk of bias tool. It has 7 dimensions, and each one is further classified as high, unclear and low risk of bias. Any different opinions between two authors will be resolved by discussion with the help of a third author.

### 2.3.5. Measures of treatment effect

Enumeration outcome data will be evaluated as risk ratio and 95% confidence intervals, and continuous outcome data will be calculated as mean difference or standardized mean difference and 95% confidence intervals.

### 2.3.6. Assessment of heterogeneity

The heterogeneity among eligible studies will be identified using *I*^2^ statistics. *I*^2^ ≤ 50% indicates minor heterogeneity, while *I*^2^ \> 50% means substantial heterogeneity.

### 2.3.7. Assessment of reporting bias

When more than 10 eligible RCTs are included, funnel plot and Egger\'s regression test will be conducted for reporting bias identification.^\[[@R25],[@R26]\]^

### 2.3.8. Subgroup analysis

We will carry out subgroup analysis to investigate the potential factors of significant heterogeneity based on the different study characteristics, treatments and controls, and outcome measurements.

### 2.3.9. Sensitivity analysis

When sufficient studies are available, we will conduct sensitivity analysis to check the stability of outcome results by removing low quality studies.

### 2.3.10. Ethics and dissemination

Ethical approval will not be required because this study will not use individual patient data. The results of this study are expected to disseminate by the publication in a peer-reviewed journal or conference proceedings.

2.4. Data synthesis
-------------------

RevMan 5.3 software will be adopted for statistical analysis. Meta-analysis will be performed if more than two or above eligible studies with minor heterogeneity at same outcome measurements will be included. If there is minor heterogeneity among sufficient studies (*I*^2^ ≤ 50%), a fixed-effect model will be used for data synthesizing, and meta-analysis will be employed. If there is significant heterogeneity among enough studies (*I*^2^ \> 50%), the source of such substantial heterogeneity will be further analyzed, a random-effect model will be used for data pooling, and subgroup analysis will be carried out. If there is still substantial heterogeneity after subgroup analysis, we will not conduct data pooling and meta-analysis. At the same time, outcome results will be reported as narrative summary.

3. Discussion
=============

Although previous studies have reported that microsurgery is utilized for the treatment of patients with CH secondary to GH, its efficacy and safety has not been assessed systematically. Thus, it is crucial to make sure whether microsurgery is a good option for the patients with CH secondary to GH. The objective of this study is to systematically assess the efficacy and safety of microsurgery for the treatment of patients with CH secondary to GH. We hope this review will provide most recent information on the credibility current evidence and research directions for both clinical practice and future studies.
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